Moderna, Inc. (MRNA) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001682852

Market Cap 25.27 Bn

P/E -7.85

P/S 11.36

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 590.00 Mn

Revenue Growth (1y) (Qtr) 260.19

Add ratio to table...

About

Moderna Inc is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). The company designs mRNA medicines to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit, with the potential to address a broad spectrum of diseases. Its platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the capability to pursue in parallel a robust pipeline of new development candidates. Moderna...

Moderna Inc is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). The company designs mRNA medicines to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit, with the potential to address a broad spectrum of diseases. Its platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the capability to pursue in parallel a robust pipeline of new development candidates. Moderna Inc is developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.

Moderna Inc generates revenue primarily from net product sales of its approved vaccines and other revenue streams including grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. Its approved products include Spikevax® and mNEXSPIKE® for COVID-19, mRESVIA® for respiratory syncytial virus (RSV), and mCOMBRIAX® for flu plus COVID combination in individuals 50 years of age and older. The company sells its COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations, with U. S. sales primarily through wholesalers and distributors, and to a lesser extent directly to retailers and healthcare providers.

The company operates through the following segments: infectious disease vaccines, oncology therapeutics, and rare disease therapeutics.

• Infectious disease vaccines: This segment focuses on the development and commercialization of mRNA-based vaccines for preventive infectious diseases. It includes approved products such as Spikevax®, mNEXSPIKE®, mRESVIA®, and mCOMBRIAX®. The segment also encompasses a diverse pipeline of vaccine candidates including seasonal flu vaccine (mRNA-1010), norovirus vaccine (mRNA-1403), and others targeting CMV, EBV, HIV, and hMPV.

• Oncology therapeutics: This segment is dedicated to creating mRNA-based therapeutics for cancer treatment. Key programs include intismeran autogene (mRNA-4157) in collaboration with Merck, which is being evaluated in multiple tumor types such as melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma. Another wholly-owned investigational cancer antigen therapy, mRNA-4359, is being studied in first-line metastatic melanoma, second-line+ metastatic melanoma, and first-line metastatic NSCLC.

• Rare disease therapeutics: This segment targets rare metabolic diseases with significant unmet medical need using mRNA therapeutics. The lead candidate is mRNA-3927 for propionic acidemia (PA), which is currently in a registrational study with target enrollment reached and potential data expected in 2026. The segment also includes mRNA-3705 for methylmalonic acidemia (MMA), for which a pivotal trial decision is being deferred until PA data readout.

Moderna Inc holds a leading position in the mRNA therapeutics industry, having pioneered the development and commercialization of mRNA-based medicines. Its competitive advantages stem from its integrated platform encompassing mRNA science, delivery technology, and manufacturing capabilities that enable rapid clinical and commercial production at scale. The company faces competition from other biotechnology and pharmaceutical firms developing mRNA and vaccine technologies, but its early mover advantage, broad intellectual property portfolio, and diversified pipeline across infectious diseases, oncology, and rare diseases differentiate it in the market.

Moderna Inc serves a diverse customer base including commercial wholesalers and distributors, retailers, healthcare providers, foreign governments, and international organizations. In the United States, its COVID and RSV vaccines are sold primarily through wholesalers and distributors, with additional sales to retailers and healthcare providers. Internationally, the company supplies vaccines to government entities under long-term strategic partnerships, supporting pandemic preparedness and public health initiatives.

Investment thesis

Bull case

Moderna’s 2025 financial performance demonstrates a disciplined execution that has translated into a 30% reduction in operating expenses and a 31% cut in R&D spend, while still maintaining a robust cash balance of $8.1 billion. The company’s ability to lower cost of sales by 41%—driven by higher productivity, reduced inventory write‑downs and the wind‑down of contract‑manufacturing costs—shows that the cost‑discipline program is delivering real, tangible results that free cash for future investment. Importantly, the company’s cash draw from the credit facility was only $600 million, a modest fraction of the $1.5 billion line, and the company achieved $1.8 billion in cash improvement over 2025 guidance. This financial leeway positions Moderna to sustain its R&D pipeline while expanding commercialization in key markets.
International growth is a cornerstone of Moderna’s 2026 outlook, with the company projecting a 10% revenue increase that is largely driven by new and expanded operations outside the United States. The company has secured multi‑year agreements with the United Kingdom, Canada, Australia, Mexico, Taiwan, and Brazil that provide access to local manufacturing, regulatory support, and distribution channels. These agreements are strategically designed to capture market share in countries where vaccination demand is rising, especially for COVID and respiratory vaccines, and the company’s own launch of MNEXT Spike in the U.S. has already secured 24% of the U.S. retail market, with a 34% share among seniors. A second year of MNEXT Spike sales is expected to build on this momentum, and the company is poised to replicate this success in Europe, Japan, and Taiwan.
Moderna’s vaccine portfolio is expanding beyond COVID‑19 to address a range of respiratory diseases, creating multiple revenue streams. The company’s RSV vaccine, Emresvia, has received approvals in 40 countries and targets both high‑risk and older adults, while the seasonal flu vaccine, mRNA‑1010, is currently under review in Europe, Canada, and Australia. Even though the U.S. FDA has deferred review of the flu program, Moderna has a clear path forward internationally and is actively preparing for a 2027 launch in the U.S. once regulatory clarity is achieved. In addition, a flu‑COVID combination vaccine is progressing through European and Canadian reviews, with a potential launch in 2026 that could generate significant incremental revenue. These products, combined with an upcoming norovirus vaccine, diversify revenue sources and reduce dependency on COVID‑19 demand.
The oncology pipeline represents a high‑impact catalyst, with five late‑stage trials across melanoma, renal cell carcinoma, muscle‑invasive bladder cancer, and other solid tumors now fully enrolled. The company’s individualized cancer therapy (INT) program, in partnership with Merck, has delivered a five‑year phase‑2 data set that shows a 50% reduction in relapse or death for adjuvant melanoma, a benchmark that could translate into a blockbuster approval if phase‑3 results confirm the trend. The company’s oncology portfolio also includes a phase‑2 study of mRNA‑4259, a cancer antigen therapy, and a phase‑1/2 study of a T‑cell engager, mRNA‑2808, for multiple myeloma, expanding the therapeutic potential beyond solid tumors. The breadth of the oncology pipeline, coupled with the partnership with Merck and the ability to bring these products to market faster due to the mRNA platform, creates an upside that could significantly lift the company’s earnings profile if the data streams remain positive.
Rare disease programs, particularly the propionic acidemia (PA) program that is fully enrolled and the upcoming methylmalonic acidemia (MMA) study, offer a stable revenue stream that is less affected by the cyclical nature of infectious disease markets. These programs target small patient populations but carry high pricing potential and strong unmet medical need, which can translate into substantial profitability once approved. The company’s ability to leverage its mRNA platform to address metabolic disorders provides a distinct competitive advantage in a niche that is underserved by traditional small‑molecule and biologic therapies. This dual focus on rare disease and oncology provides a balanced portfolio that can offset revenue volatility associated with the COVID and respiratory vaccine markets.

Moderna’s 2025 financial performance demonstrates a disciplined execution that has translated into a 30% reduction in operating expenses and a 31% cut in R&D spend, while still maintaining a robust cash balance of $8.1 billion. The company’s ability to lower cost of sales by 41%—driven by higher productivity, reduced inventory write‑downs and the wind‑down of contract‑manufacturing costs—shows that the cost‑discipline program is delivering real, tangible results that free cash for future investment. Importantly, the company’s cash draw from the credit facility was only $600 million, a modest fraction of the $1.5 billion line, and the company achieved $1.8 billion in cash improvement over 2025 guidance. This financial leeway positions Moderna to sustain its R&D pipeline while expanding commercialization in key markets.
International growth is a cornerstone of Moderna’s 2026 outlook, with the company projecting a 10% revenue increase that is largely driven by new and expanded operations outside the United States. The company has secured multi‑year agreements with the United Kingdom, Canada, Australia, Mexico, Taiwan, and Brazil that provide access to local manufacturing, regulatory support, and distribution channels. These agreements are strategically designed to capture market share in countries where vaccination demand is rising, especially for COVID and respiratory vaccines, and the company’s own launch of MNEXT Spike in the U.S. has already secured 24% of the U.S. retail market, with a 34% share among seniors. A second year of MNEXT Spike sales is expected to build on this momentum, and the company is poised to replicate this success in Europe, Japan, and Taiwan.
Moderna’s vaccine portfolio is expanding beyond COVID‑19 to address a range of respiratory diseases, creating multiple revenue streams. The company’s RSV vaccine, Emresvia, has received approvals in 40 countries and targets both high‑risk and older adults, while the seasonal flu vaccine, mRNA‑1010, is currently under review in Europe, Canada, and Australia. Even though the U.S. FDA has deferred review of the flu program, Moderna has a clear path forward internationally and is actively preparing for a 2027 launch in the U.S. once regulatory clarity is achieved. In addition, a flu‑COVID combination vaccine is progressing through European and Canadian reviews, with a potential launch in 2026 that could generate significant incremental revenue. These products, combined with an upcoming norovirus vaccine, diversify revenue sources and reduce dependency on COVID‑19 demand.
The oncology pipeline represents a high‑impact catalyst, with five late‑stage trials across melanoma, renal cell carcinoma, muscle‑invasive bladder cancer, and other solid tumors now fully enrolled. The company’s individualized cancer therapy (INT) program, in partnership with Merck, has delivered a five‑year phase‑2 data set that shows a 50% reduction in relapse or death for adjuvant melanoma, a benchmark that could translate into a blockbuster approval if phase‑3 results confirm the trend. The company’s oncology portfolio also includes a phase‑2 study of mRNA‑4259, a cancer antigen therapy, and a phase‑1/2 study of a T‑cell engager, mRNA‑2808, for multiple myeloma, expanding the therapeutic potential beyond solid tumors. The breadth of the oncology pipeline, coupled with the partnership with Merck and the ability to bring these products to market faster due to the mRNA platform, creates an upside that could significantly lift the company’s earnings profile if the data streams remain positive.
Rare disease programs, particularly the propionic acidemia (PA) program that is fully enrolled and the upcoming methylmalonic acidemia (MMA) study, offer a stable revenue stream that is less affected by the cyclical nature of infectious disease markets. These programs target small patient populations but carry high pricing potential and strong unmet medical need, which can translate into substantial profitability once approved. The company’s ability to leverage its mRNA platform to address metabolic disorders provides a distinct competitive advantage in a niche that is underserved by traditional small‑molecule and biologic therapies. This dual focus on rare disease and oncology provides a balanced portfolio that can offset revenue volatility associated with the COVID and respiratory vaccine markets.

Bear case

The U.S. FDA’s refusal to file the mRNA‑1010 flu vaccine and the resulting uncertainty in the Type A meeting present a significant regulatory risk that could delay or even eliminate the company’s U.S. flu product launch. Without a U.S. presence, Moderna loses access to a market that, while smaller than the U.K. and Canada, still represents a multi‑billion‑dollar opportunity, especially for high‑risk populations. The company’s financial guidance for 2026 explicitly assumes no revenue from the flu or flu‑COVID combination in the United States, which underestimates the potential revenue loss if the U.S. market remains inaccessible. This regulatory setback also raises questions about the company’s ability to secure approvals for other respiratory products, such as the flu‑COVID combo, further dampening growth prospects.
Moderna’s heavy R&D spend—approximately $3 billion in 2026—combined with a net loss of $2.8 billion in 2025, highlights a sustainability concern. Even with a $5.5‑$6 billion cash balance at the end of 2026, the company’s burn rate is such that it could exhaust its runway if revenue growth stalls or if additional capital raises dilute shareholders. The company’s guidance assumes a $5.5‑$6 billion cash balance after 2026, but it does not account for potential cost overruns, unexpected regulatory delays, or lower-than‑expected product uptake, all of which could accelerate cash depletion. Investors may view this as a significant risk factor, especially in a capital‑intensive industry where market share can be lost quickly to competitors.
The COVID‑19 vaccine market, once a windfall source, is now a declining segment with shrinking demand. Moderna’s revenue share from COVID vaccines fell from 62% to 48% in 2026, a trend that may continue as competitors gain scale and market share, and as payers push for lower pricing. The company’s reliance on the MNEXT Spike launch to drive second‑year growth is a high‑stakes bet, and any slowdown in senior vaccination rates—due to public sentiment or regulatory changes—could severely impact revenue forecasts. The company’s financial guidance already reflects a “future potential decline” in COVID vaccination rates, indicating an awareness that this segment will not rebound to pandemic levels.
Competitive pressures in both the respiratory and oncology spaces could erode Moderna’s market position. Several other mRNA and traditional vaccine manufacturers are advancing similar products, and some—like Pfizer and Johnson & Johnson—have deep commercial pipelines and broader manufacturing networks. In oncology, the field is highly crowded, and the success of the INT program depends on event‑driven data that may not meet regulatory expectations. A failure in the phase‑3 melanoma data or a lack of clinical benefit in renal cell carcinoma or bladder cancer would diminish the attractiveness of the entire oncology portfolio and reduce future revenue streams.
Pricing and reimbursement uncertainties loom large, especially in the United States. Recent policy shifts, such as the cancellation of the $600 million government contract for high‑risk mRNA vaccine development, reflect a broader skepticism toward mRNA technology that could translate into payer hesitancy. If payers view the company’s new respiratory products as too expensive relative to existing alternatives, the company may have to offer discounts that erode margins. This risk is amplified by the fact that many new products—especially in rare disease—are priced at a premium, and reimbursement pathways for high‑cost therapies are still evolving.

The U.S. FDA’s refusal to file the mRNA‑1010 flu vaccine and the resulting uncertainty in the Type A meeting present a significant regulatory risk that could delay or even eliminate the company’s U.S. flu product launch. Without a U.S. presence, Moderna loses access to a market that, while smaller than the U.K. and Canada, still represents a multi‑billion‑dollar opportunity, especially for high‑risk populations. The company’s financial guidance for 2026 explicitly assumes no revenue from the flu or flu‑COVID combination in the United States, which underestimates the potential revenue loss if the U.S. market remains inaccessible. This regulatory setback also raises questions about the company’s ability to secure approvals for other respiratory products, such as the flu‑COVID combo, further dampening growth prospects.
Moderna’s heavy R&D spend—approximately $3 billion in 2026—combined with a net loss of $2.8 billion in 2025, highlights a sustainability concern. Even with a $5.5‑$6 billion cash balance at the end of 2026, the company’s burn rate is such that it could exhaust its runway if revenue growth stalls or if additional capital raises dilute shareholders. The company’s guidance assumes a $5.5‑$6 billion cash balance after 2026, but it does not account for potential cost overruns, unexpected regulatory delays, or lower-than‑expected product uptake, all of which could accelerate cash depletion. Investors may view this as a significant risk factor, especially in a capital‑intensive industry where market share can be lost quickly to competitors.
The COVID‑19 vaccine market, once a windfall source, is now a declining segment with shrinking demand. Moderna’s revenue share from COVID vaccines fell from 62% to 48% in 2026, a trend that may continue as competitors gain scale and market share, and as payers push for lower pricing. The company’s reliance on the MNEXT Spike launch to drive second‑year growth is a high‑stakes bet, and any slowdown in senior vaccination rates—due to public sentiment or regulatory changes—could severely impact revenue forecasts. The company’s financial guidance already reflects a “future potential decline” in COVID vaccination rates, indicating an awareness that this segment will not rebound to pandemic levels.
Competitive pressures in both the respiratory and oncology spaces could erode Moderna’s market position. Several other mRNA and traditional vaccine manufacturers are advancing similar products, and some—like Pfizer and Johnson & Johnson—have deep commercial pipelines and broader manufacturing networks. In oncology, the field is highly crowded, and the success of the INT program depends on event‑driven data that may not meet regulatory expectations. A failure in the phase‑3 melanoma data or a lack of clinical benefit in renal cell carcinoma or bladder cancer would diminish the attractiveness of the entire oncology portfolio and reduce future revenue streams.
Pricing and reimbursement uncertainties loom large, especially in the United States. Recent policy shifts, such as the cancellation of the $600 million government contract for high‑risk mRNA vaccine development, reflect a broader skepticism toward mRNA technology that could translate into payer hesitancy. If payers view the company’s new respiratory products as too expensive relative to existing alternatives, the company may have to offer discounts that erode margins. This risk is amplified by the fact that many new products—especially in rare disease—are priced at a premium, and reimbursement pathways for high‑cost therapies are still evolving.

Customer Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ATHE	Alterity Therapeutics Ltd	925,601.88 Bn	-	50.75 Mn	-
2	BLTE	Belite Bio, Inc	58,560.00 Bn	-95.69	-	-
3	QNTM	Quantum Biopharma Ltd.	17,284.41 Bn	0.76	-	-
4	LEGN	Legend Biotech Corp	2,809.00 Bn	0.00	0.00 Mn	319.10 Mn
5	EVAX	Evaxion A/S	1,334.43 Bn	0.00	0.00 Mn	-
6	AKTX	Akari Therapeutics Plc	1,312.27 Bn	-44,753.60	-	-
7	PBM	Psyence Biomedical Ltd.	212.16 Bn	10.84	-	-
8	VRTX	Vertex Pharmaceuticals Inc / Ma	114.83 Bn	26.57	0.00 Mn	-

Research Tools

Developers

Moderna, Inc. (NASDAQ: MRNA)

About

Investment thesis

Bull case

Bear case

Customer Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Moderna, Inc. (NASDAQ: MRNA)

About

Investment thesis

Bull case

Bear case

Customer Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password